Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Divis Laboratories Ltd.'s net profit margin of 22.6% in FY2025 reflects excellent profitability, with operating margin at 30.0% and gross margin at 61.6%.
In FY 2025, Divis Laboratories Ltd. posted a gross margin of 61.6%, an operating margin of 30.0%, a net margin of 22.6%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Divis Laboratories Ltd.'s revenue grew 18.7% to 97.12B and net profit grew 36.9% to 21.91B YoY in FY2025, indicating healthy business momentum.
In FY 2025, Divis Laboratories Ltd.'s revenue grew by 18.7% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Divis Laboratories Ltd.'s ROE of 14.6% in FY2025 indicates moderate shareholder returns.
In FY 2025, Divis Laboratories Ltd. reported an ROE of 14.6%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Divis Laboratories Ltd.'s FCF/NI ratio of 0.10x in FY2025 indicates weak cash generation raising concerns about earnings quality.
In FY 2025, Divis Laboratories Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Divis Laboratories Ltd.'s OCF/NI ratio of 0.75x in FY2025 indicates reasonable cash conversion from operations.
In FY 2025, Divis Laboratories Ltd.'s operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Divis Laboratories Ltd.'s current ratio of 6.94x in FY2025 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2025, Divis Laboratories Ltd. reported a current ratio of 6.94. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Divis Laboratories Ltd.'s interest coverage ratio of 1,459.0x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Divis Laboratories Ltd. reported an interest coverage ratio of 1,459.0x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Divis Laboratories Ltd.'s debt-to-equity ratio of 0.00x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Divis Laboratories Ltd. reported a debt-to-equity ratio of 0.00. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Divis Laboratories Ltd.'s debt increased 33.3% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Divis Laboratories Ltd.'s total debt increased by 33.3% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Divis Laboratories Ltd.'s diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 265.48M.
In FY 2025, Divis Laboratories Ltd.'s diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025